ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

A STUDY TO DETERMINE WHETHER HOW MUCH EFFECTIVE USING ASPIRIN PROVES IN TERMS OF MORTALITY REDUCTION WHILE TREATING TUBERCULOUS MENINGITIS

Dr. Sana Zafar, Dr. Sidra Rafiq, Dr. Aleema Hasan

Objectives: The research objective is the evaluation of aspirin effect on the occurrence of mortality within two months of TBM (Tuberculous Meningitis) stage-III treatment among (1 to 15) years age patients. Materials & Methods: The research method is a randomised open-label placebo-controlled trial, carried out at Mayo Hospital, Lahore from February to September 2017. We selected 162 (1 – 15) years’ patients with stage-III TBM. We divided patients between Group – A (Aspirin) and Group – B (Placebo) consisting 81 patients each. We recorded mortality as an outcome for both groups. We treated each patient with 04 anti-tubercular drugs; RHZE regimen (per-oral for two months daily) including Isoniazid (10 mg/kg), Rifampicin (15 mg/kg), Ethambutol (15 mg/kg), and Pyrazinamide (25 mg/kg), then RH (for ten months) including Isoniazid (10 mg/kg) and Rifampicin (15 mg/kg) with Corticosteroid (for one month) including Prednisolone (1 – 2 mg/kg) and tapered in four coming weeks. However, Group – A patient only received (60 mg/kg)/day of oral aspirin divided 12-hourly with the start of anti-tubercular therapy 1st dose. Results: The number of male and female patients was 48.80% (79) and 51.20% (83) respectively. Out of 162 patients, 65.40% (106) were having (6 – 10) year’s age. We found Miliary and severe wasting among 19.10% (31) and 24.70% (40) patients respectively. We noted a 26.50% (43) mortality among patient children. After we divided groups, we found variables statistically not significant having P-value > 0.050. Conclusion: Aspirin proves to be reducing mortality among TBM (stage-III) children with no statistical significance achieved. Keywords: Tuberculous Meningitis (TBM), Tuberculosis (TB), Miliary Tuberculosis (MTB) and Aspirin.

FULL TEXT